47 results
8-K
EX-99.2
LYEL
Lyell Immunopharma, Inc.
26 Jun 24
Regulation FD Disclosure
8:32am
stemness and cell death Proliferation & cell differentiation Tumor antigen Tumor cell Repeat antigen stimulation T-cell exhaustion – 6 ©2024 Lyell
8-K
LYEL
Lyell Immunopharma, Inc.
20 Nov 23
Departure of Directors or Certain Officers
4:26pm
) a Change in Control, as defined in the Company’s Officer Severance Plan; and (iii) the optionholder’s death or Disability (as defined
DEF 14A
p4nd8h1s1pl8c cyf6tw
28 Apr 22
Definitive proxy
4:11pm
10-K
EX-10.8
lzy865rfgr80y2cy9aw
29 Mar 22
Annual report
4:20pm
8-K
3v5by7pqzy93m9b4
15 Feb 22
Departure of Directors or Certain Officers
4:47pm
S-8
EX-4.1
t1zb1gml
21 Jun 21
Registration of securities for employees
5:08pm
S-8
EX-99.3
98jslk
21 Jun 21
Registration of securities for employees
5:08pm
S-8
EX-4.2
xgwse tvkoyk
21 Jun 21
Registration of securities for employees
5:08pm
424B4
zd59r6xus79
18 Jun 21
Prospectus supplement with pricing info
12:00am
S-1/A
EX-10.4
h77vx kn62aulj8l
9 Jun 21
IPO registration (amended)
7:12am
S-1/A
ch5 ynrbv1
9 Jun 21
IPO registration (amended)
7:12am
S-1/A
EX-3.4
teqfsjy0ad7col
9 Jun 21
IPO registration (amended)
7:12am
S-1/A
EX-10.3
s7rxkzj4nzvzdyoz6
9 Jun 21
IPO registration (amended)
7:12am
S-1/A
EX-3.2
vzu0u67a2nykup4rfq
9 Jun 21
IPO registration (amended)
7:12am
S-1
EX-10.11
pw1 m95d9tb
25 May 21
IPO registration
5:28pm
S-1
EX-10.22
g6m uwbvpg
25 May 21
IPO registration
5:28pm